Focus Partners Wealth
TAK icon

Focus Partners Wealth’s Takeda Pharmaceutical TAK Stock Holding History

Focus Partners Wealth’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
679,950
+197,563
+41% +$3.27M 0.01% 692
2026
Q1 		$8.87M Sell
482,387
-79,662
-14% -$1.4M 0.01% 754
2025
Q4 		$8.76M Buy
562,049
+461,458
+459% +$6.6M 0.01% 749
2025
Q3 		$1.47M Buy
100,591
+10,815
+12% +$161K ﹤0.01% 1131
2025
Q2 		$1.39M Buy
89,776
+7,038
+9% +$104K ﹤0.01% 1015
2025
Q1 		$1.23M Buy
82,738
+3,094
+4% +$43.4K ﹤0.01% 991
2024
Q4 		$1.05M Buy
79,644
+64,693
+433% +$889K ﹤0.01% 1042
2024
Q3 		$213K Sell
14,951
-112,855
-88% -$1.6M ﹤0.01% 1442
2024
Q2 		$1.68M Buy
127,806
+64,982
+103% +$860K 0.01% 689
2024
Q1 		$873K Buy
+62,824
New +$914K 0.01% 631

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Focus Partners Wealth's TAK Position: Q2 2026 in Review

Focus Partners Wealth increased its Takeda Pharmaceutical (TAK) stake by 41% in Q2 2026, buying an estimated $3.27M and bringing the position to 679,950 shares worth $10.9M. The position accounts for 0.01% of the portfolio, ranked #692.

Focus Partners Wealth first reported a position in TAK in Q1 2024 and has held it in 10 quarters since. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Focus Partners Wealth held 679,950 shares of Takeda Pharmaceutical worth $10.9M as of Q2 2026.
  • Focus Partners Wealth bought 197,563 Takeda Pharmaceutical shares in Q2 2026, an estimated $3.27M.
  • Takeda Pharmaceutical made up 0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #692 holding.
  • Focus Partners Wealth first reported a position in Takeda Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.